Non surgical facial reshaping using MD Codes

Established clinical practices use hyaluronic acid (HA) fillers to address facial volume loss. These treatments typically involve deep injection for structural support and superficial injection for contouring. However, a standardized protocol for full-face rejuvenation has remained limited. Prior research has shown that HA fillers and onabotulinumtoxinA can improve facial aesthetics, but the specific combination and placement remain underexplored. This gap motivated the development of the MD Codes approach as a potential framework for full-face rejuvenation. No prior work had resolved how to systematically apply HA fillers and onabotulinumtoxinA across multiple facial regions. The need for a reproducible methodology led to this retrospective study. The study aimed to assess whether a structured injection protocol could yield consistent aesthetic outcomes. The absence of a widely accepted protocol for full-face rejuvenation created a need for further investigation.

The study aimed to evaluate the clinical efficacy, patient satisfaction, and safety of the MD Codes approach for full-face rejuvenation. This method proposes a standardized injection protocol using HA fillers and onabotulinumtoxinA. The specific problem addressed was the lack of a reproducible framework for facial rejuvenation. The motivation stemmed from the need to provide a consistent and effective treatment plan. The study focused on whether the MD Codes approach could deliver measurable aesthetic improvements. The researchers sought to determine if this method could be safely applied across multiple facial regions. The study also aimed to quantify patient satisfaction and assess potential complications. The goal was to establish a validated protocol for non-surgical facial rejuvenation.

This study used a retrospective, single-center design to assess the MD Codes approach. A total of 250 consecutive patients received HA fillers and onabotulinumtoxinA treatments. The study population included adults with a mean age of 39.4 ± 11.6 years, with 80.4% being female. Treatments followed a structured protocol based on the MD Codes system. HA fillers were injected into the midface region for all patients. Additional injections occurred in the upper and lower face regions for a subset of patients. OnabotulinumtoxinA was administered to all participants as part of the treatment plan. Patient outcomes were measured using the FACE-Q Appearance-Related Psychosocial Distress score. Complications were recorded and analyzed to assess treatment safety.

The study found that the MD Codes approach led to significant aesthetic improvements. The mean number of HA filler syringes used was 14 ± 4, with older patients requiring more syringes. The FACE-Q score decreased from 54.3 ± 9.3 pre-treatment to 36.1 ± 8.9 at 3 months post-treatment (P < 0.05). These results suggest a notable improvement in appearance-related distress. The most common complications included bruising (35.2%) and transient soft-tissue edema (14.0%). Prolonged periorbital edema occurred in 3.6% of cases. No major safety issues were observed during the study period. The findings support the clinical viability of the MD Codes approach for full-face rejuvenation.

The MD Codes approach for full-face rejuvenation provides significant aesthetic improvements. The study observed a decrease in appearance-related distress scores over time. No major safety concerns were reported in the patient cohort. The treatment protocol involved HA fillers and onabotulinumtoxinA administered in a structured manner. The most common complications were bruising and transient edema, which resolved without intervention. The findings suggest that the MD Codes approach is a safe and effective treatment option. The observed improvements in patient satisfaction support the use of this standardized protocol. The study does not propose future directions or drug targets beyond the treatment outcomes observed.